Last reviewed · How we verify
NCT07518420
Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomach Disharmony Syndrome
NA trial testing Chaizhi Hewei Decoction in Non-erosive Reflux Disease (NERD) in 66 participants. Not yet recruiting.
1 March 2028
Quick facts
| Lead sponsor | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 15 May 2026 |
| Primary completion | 1 March 2028 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chaizhi Hewei Decoction
- Placebo
Conditions studied
- Non-erosive Reflux Disease (NERD) — all drugs for Non-erosive Reflux Disease (NERD) →
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Who can join
Adults 18 to 70, any sex, with Non-erosive Reflux Disease (NERD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study focuses on patients with NERD (gastroesophageal reflux disease) and liver-gallbladder disharmony syndrome as its research subjects. It conducts a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the Chai Zhi He Wei formula in terms of symptom improvement, quality of life, and adverse reactions. On one hand, this research aims to enhance the level of evidence-based medicine for TCM syndrome differentiation and treatment of NERD. On the other hand, it seeks to reduce the dosage of PPIs (proton pump inhibitors) or discontinue their use, addressing the side effects caused by PPI overuse, and serving as a leading example for TCM clinical research. Lastly, the study aims to optimize the efficacy of Tongjiang granules and address potential safety concerns, such as diarrhea.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07518420
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xiyuan Hospital of China Academy of Chinese Medical Sciences trials
Trials by the same sponsor.
- NCT06845254 — Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrom · Phase 3 · not yet recruiting
- NCT06618495 — Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome · Phase 1, PHASE2 · completed
- NCT06311890 — Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderat · Phase 2 · recruiting
- NCT05638672 — COVID-19 Huashi Baidu Formula Clinical Study · NA · unknown
- NCT05761652 — An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07518420 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07518420.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing